Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


Global cellular response to chemotherapy-induced apoptosis.

Wiita AP, Ziv E, Wiita PJ, Urisman A, Julien O, Burlingame AL, Weissman JS, Wells JA.

Elife. 2013 Oct 29;2:e01236. doi: 10.7554/eLife.01236. Erratum in: Elife. 2013;2:e01816.


Dissecting apoptosis the omics way.

Van Damme P.

Elife. 2013 Nov 12;2:e01587. doi: 10.7554/eLife.01587.


KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA.

Blood. 2012 Feb 9;119(6):1450-8. doi: 10.1182/blood-2011-04-346676. Epub 2011 Dec 5.


The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19.


Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL, Atanackovic D, Colleoni GW.

PLoS One. 2011;6(11):e27707. doi: 10.1371/journal.pone.0027707. Epub 2011 Nov 16.


JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.

Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.

Apoptosis. 2006 Apr;11(4):607-25.


Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.

Blood. 2012 Jan 19;119(3):826-37. doi: 10.1182/blood-2011-07-366492. Epub 2011 Nov 29. Erratum in: Blood. 2014 Jul 24;124(4):663. De Bryune, Elke [corrected to De Bruyne, Elke].


A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC.

Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6.


Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.

Balsas P, Galán-Malo P, Marzo I, Naval J.

Leuk Res. 2012 Feb;36(2):212-8. doi: 10.1016/j.leukres.2011.09.011. Epub 2011 Oct 5.


Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.

Gu H, Chen X, Gao G, Dong H.

Mol Cancer Ther. 2008 Aug;7(8):2298-307. doi: 10.1158/1535-7163.MCT-08-0186.


A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.

Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC.

Oncogene. 2008 Jan 31;27(6):721-31. Epub 2007 Jul 23.


A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.

Yerlikaya A, Okur E, Baykal AT, Acılan C, Boyacı I, Ulukaya E.

J Proteomics. 2015 Jan 15;113:315-25. doi: 10.1016/j.jprot.2014.09.010. Epub 2014 Oct 8.


Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.

Teraishi F, Guo W, Zhang L, Dong F, Davis JJ, Sasazuki T, Shirasawa S, Liu J, Fang B.

Cancer Res. 2006 Jun 15;66(12):6072-9.


Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C.

Cancer Res. 2008 Nov 15;68(22):9323-30. doi: 10.1158/0008-5472.CAN-08-2873.


The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.


Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.

Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.

Oncogene. 2005 Jul 21;24(31):4993-9.


Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.

Perez LE, Parquet N, Meads M, Anasetti C, Dalton W.

Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.


Supplemental Content

Support Center